Future Market Insights.png
Cell Culture Market is Projected to Grow at a Stupendous CAGR of 11.9%, Surpassing a Revenue of Around US$ 75 Bn During Forecast Period of 2022-32 | Future Market Insights, Inc.
December 06, 2022 06:30 ET | Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Dec. 06, 2022 (GLOBE NEWSWIRE) -- The global cell culture market is anticipated to grow at a stupendous CAGR of approximately 11.9% throughout the forecast period from 2022 to 2032. The...
AmplifyBio Chooses Blue Mountain to Achieve GMP Compliance and Advance Digital Strategy
December 01, 2022 09:30 ET | AmplifyBio
WEST JEFFERSON, Ohio, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Amplify Bio has selected Blue Mountain Regulatory Asset Manager (RAM) to help with incorporating industry best practices and ensuring...
logo.png
Cell and Gene Therapy Market Size to Surpass USD 93.78 BN by 2030
November 30, 2022 07:00 ET | Precedence Research
Ottawa, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Latest Research Study on “Cell and Gene Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030”. ...
BioBridge Global Expanding Efforts and Reach into Advanced Therapies
November 02, 2022 14:39 ET | BioBridge Global
San Antonio, Texas, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BioBridge Global, a nonprofit healthcare services organization, announced today that, building on the success of GenCure, its wholly owned...
EW Healthcare Partners Announces Acquisition of Germfree Laboratories, Inc.
October 18, 2022 12:46 ET | EW Healthcare Partners
NEW YORK and ORMAND BEACH, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- EW Healthcare Partners announced today that it has acquired Germfree Laboratories, Inc., a leading U.S. manufacturer of turnkey,...
EW Healthcare Partners Acquires Germfree Laboratories, Inc.
October 18, 2022 12:16 ET | EW Healthcare Partners
NEW YORK and ORMAND BEACH, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- EW Healthcare Partners announced today that it has acquired Germfree Laboratories, Inc., a leading U.S. manufacturer of turnkey,...
NorthX_tworow_color_RGB.jpg
Helena Strigård ny vd för snabbt expanderande NorthX Biologics
September 20, 2022 01:00 ET | NorthX Biologics Matfors AB
MATFORS, Sweden, Sept. 20, 2022 (GLOBE NEWSWIRE) -- NorthX Biologics (“NorthX”) styrelse har utsett Helena Strigård till ny vd. Hon kommer närmast från rollen som vd för branschorganisationen...
NorthX_tworow_color_RGB.jpg
Helena Strigård appointed as new CEO of rapidly expanding NorthX Biologics
September 20, 2022 01:00 ET | NorthX Biologics Matfors AB
MATFORS, Sweden, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The Board of NorthX Biologics ("NorthX") has appointed Helena Strigård as the new CEO. She joins NorthX from her role as Director General for the...
NOVARTIS logo.jpg
Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
June 12, 2022 05:30 ET | Novartis Pharma AG
In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after more than...
NOVARTIS logo.jpg
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
May 27, 2022 18:58 ET | Novartis Pharma AG
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah...